Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to help ensure cooperation between NICE and the pharmaceutical industry to provide all stem cell transplant patients with adequate access to new Graft-versus-Host Disease treatments.

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on the clinical and cost effectiveness of all new medicines and aims to publish guidance close to the point of licensing wherever possible. The NHS in England is legally required to make funding available for medicines in line with NICE’s recommendations. NICE works closely with pharmaceutical companies and other stakeholders in the development of its recommendations on individual treatments.

NICE is developing technology appraisal guidance on belumosudil for treating chronic graft versus host disease after two or more lines of systemic therapy and expects to publish final guidance in November 2023.